Tags

Type your tag names separated by a space and hit enter

The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease.

Abstract

BACKGROUND

Tegaserod (HTF 919), a 5-HT4 receptor partial agonist, has prokinetic effects that might be useful in decreasing acid reflux in gastro-oesophageal reflux disease (GERD).

METHODS

To investigate the potential clinical utility of tegaserod in GERD, a five-period crossover study (balanced Latin square) was designed to evaluate the efficacy of 4 b.d. doses of tegaserod vs. placebo. Four-hour manometry (1 h fasting and 3 h postprandial) with continuous recording of lower oesophageal sphincter pressure and distal oesophageal pH, was performed at the end of each 2-week treatment period in 19 patients with mild-to-moderate GERD. Recordings were scored for mean lower oesophageal sphincter pressure, number of transient lower oesophageal sphincter relaxations, and distal oesophageal acid exposure.

RESULTS

Tegaserod (1 mg/day and 4 mg/day) caused a more than 50% decrease in acid exposure in the postprandial period in patients with abnormal acid exposure, although only the 1 mg/day tegaserod treatment elicited statistically significant decreasing (P < 0.05) for the entire treatment group (percentage time for which pH < 4: placebo=13%; 1 mg/day dose=5%; 4 mg/day dose=8%). A decreased number of reflux episodes was demonstrated with both the 1 mg/day and 4 mg/day tegaserod doses. There was no apparent effect on mean lower oesophageal sphincter pressure, whilst transient lower oesophageal sphincter relaxations frequency decreased in the 1-2.5 h post-dose.

CONCLUSIONS

Tegaserod in a dose of 1 mg/day causes a significant decrease in postprandial oesophageal acid exposure. The reduction in oesophageal acid exposure with tegaserod treatment may result from enhanced oesophageal acid clearance, improved gastric emptying, and/or reduced transient lower oesophageal sphincter relaxations.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Northwestern University Medical School, Chicago, Illinois 60611, USA. p_kahrilas@northwestern.edu

    , ,

    Source

    MeSH

    Adult
    Cross-Over Studies
    Dose-Response Relationship, Drug
    Double-Blind Method
    Esophagogastric Junction
    Female
    Gastric Acid
    Gastroesophageal Reflux
    Gastrointestinal Agents
    Humans
    Indoles
    Male
    Manometry
    Postprandial Period
    Pressure
    Treatment Outcome

    Pub Type(s)

    Clinical Trial
    Journal Article
    Multicenter Study
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    11069322

    Citation

    Kahrilas, P J., et al. "The Effects of Tegaserod (HTF 919) On Oesophageal Acid Exposure in Gastro-oesophageal Reflux Disease." Alimentary Pharmacology & Therapeutics, vol. 14, no. 11, 2000, pp. 1503-9.
    Kahrilas PJ, Quigley EM, Castell DO, et al. The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000;14(11):1503-9.
    Kahrilas, P. J., Quigley, E. M., Castell, D. O., & Spechler, S. J. (2000). The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. Alimentary Pharmacology & Therapeutics, 14(11), pp. 1503-9.
    Kahrilas PJ, et al. The Effects of Tegaserod (HTF 919) On Oesophageal Acid Exposure in Gastro-oesophageal Reflux Disease. Aliment Pharmacol Ther. 2000;14(11):1503-9. PubMed PMID: 11069322.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastro-oesophageal reflux disease. AU - Kahrilas,P J, AU - Quigley,E M, AU - Castell,D O, AU - Spechler,S J, PY - 2000/11/9/pubmed PY - 2001/2/28/medline PY - 2000/11/9/entrez SP - 1503 EP - 9 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 14 IS - 11 N2 - BACKGROUND: Tegaserod (HTF 919), a 5-HT4 receptor partial agonist, has prokinetic effects that might be useful in decreasing acid reflux in gastro-oesophageal reflux disease (GERD). METHODS: To investigate the potential clinical utility of tegaserod in GERD, a five-period crossover study (balanced Latin square) was designed to evaluate the efficacy of 4 b.d. doses of tegaserod vs. placebo. Four-hour manometry (1 h fasting and 3 h postprandial) with continuous recording of lower oesophageal sphincter pressure and distal oesophageal pH, was performed at the end of each 2-week treatment period in 19 patients with mild-to-moderate GERD. Recordings were scored for mean lower oesophageal sphincter pressure, number of transient lower oesophageal sphincter relaxations, and distal oesophageal acid exposure. RESULTS: Tegaserod (1 mg/day and 4 mg/day) caused a more than 50% decrease in acid exposure in the postprandial period in patients with abnormal acid exposure, although only the 1 mg/day tegaserod treatment elicited statistically significant decreasing (P < 0.05) for the entire treatment group (percentage time for which pH < 4: placebo=13%; 1 mg/day dose=5%; 4 mg/day dose=8%). A decreased number of reflux episodes was demonstrated with both the 1 mg/day and 4 mg/day tegaserod doses. There was no apparent effect on mean lower oesophageal sphincter pressure, whilst transient lower oesophageal sphincter relaxations frequency decreased in the 1-2.5 h post-dose. CONCLUSIONS: Tegaserod in a dose of 1 mg/day causes a significant decrease in postprandial oesophageal acid exposure. The reduction in oesophageal acid exposure with tegaserod treatment may result from enhanced oesophageal acid clearance, improved gastric emptying, and/or reduced transient lower oesophageal sphincter relaxations. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/11069322/The_effects_of_tegaserod__HTF_919__on_oesophageal_acid_exposure_in_gastro_oesophageal_reflux_disease_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=0269-2813&amp;date=2000&amp;volume=14&amp;issue=11&amp;spage=1503 DB - PRIME DP - Unbound Medicine ER -